NPM1 and acute myeloid leukemia: In total, 35 patients were treated at the active Enzomenib dose: 22 patients had KMT2A-rearranged AML (20 AML and 2 ALL) with an ORR of 59% and a CR + CRi of 22.7%; 13 NPM1-mutant AML patients had an ORR of 53.8% and a CR + CRi of 23% [120].